Sawbones: Hepatitis B

Key Takeaways

Hepatitis B is a liver inflammation, historically known as epidemic jaundice, with early transmission via contaminated bodily fluids.
Dr. Bloomberg's discovery of the 'Australia antigen' in the 1950s identified Hepatitis B's cause, leading to vaccine development.
The Hepatitis B vaccine evolved from human plasma to genetically engineered yeast cells by 1990, enhancing safety and production.
Mandatory infant Hepatitis B vaccination since 1991 has prevented an estimated 500,000 childhood infections and 90,000 deaths.
Despite recent changes in recommendations, the Hepatitis B vaccine remains exceptionally safe and effective against severe disease and liver cancer.

The "Sawbones" podcast, offering medical history for entertainment, initiated this episode on the Hepatitis B vaccine.
The topic was prompted by host Justin McElroy sustaining an accidental cut, leading to a tetanus shot and a realization about his vaccine status.

Hepatitis is defined as inflammation of the liver, with Hepatitis B historically known as epidemic jaundice or serum hepatitis.
Early transmission routes, traced back to Hippocrates, included contamination of smallpox vaccine made with human tissue, unscreened blood products, and needle-sharing practices in medical settings.

The identification of epidemic jaundice as a distinct, contagious condition led to the theoretical postulation of viruses before direct observation was possible.
Dr. Bloomberg's early 1950s research, initially focused on genetic disease susceptibility, led to the discovery of an unusual protein named the 'Australia antigen' from global blood samples.

The 'Australia antigen' was identified as the cause of Hepatitis B, a discovery that earned Dr. Bloomberg the Nobel Prize in 1967.
The late 1960s also marked a pivotal era when virus visualization became possible, facilitating vaccine development.
Modern advancements in antibiotics, sanitation, and vaccination mean viruses like Hepatitis B do not need to be a source of fear.

A discussion ensued regarding the phrase 'do your own research,' exploring the practicality and methodology of independent research.
The conversation touched upon the challenges of relying solely on expert opinions versus abstract data.

The early Hepatitis B vaccine, developed by Drs. Bloomberg and Millman, was initially sourced from human plasma, posing risks and production challenges.
Production in the late 1970s and early 1980s lacked HIV screening, fueling public concerns and ethical debates despite the vaccine's effectiveness.
In 1990, vaccine production shifted to genetically engineered yeast cells, eliminating infection risks by producing only the surface antigen.

Hepatitis B primarily transmits through bodily fluids via sexual contact, blood, and shared needles; blood transfusion risk is mitigated by modern screening.
Infection can be asymptomatic or cause nonspecific symptoms, followed by a 1-3 week jaundice phase with severe illness, including loss of appetite and abdominal pain.
While most adult infections resolve, up to 90% of newborn infections become chronic, often transmitted from infected mothers during birth, leading to cirrhosis, liver cancer, or death.

The Hepatitis B vaccine is exceptionally safe and effective, with no evidence linking it to deaths or serious complications like Guillain-Barre syndrome.
Since its mandate for newborns in 1991, the vaccine has prevented an estimated 500,000 childhood infections and 90,000 childhood deaths.
The vaccine is considered a cancer prevention tool, protecting infants from severe long-term consequences of transmission from infected mothers, caregivers, or contaminated surfaces.